Evidence map›Paper›PMID 37976569›Full record

ArticleNeoplasia (New York, N.Y.)2023

Hepatocellular loss of mTOR aggravates tumor burden in nonalcoholic steatohepatitis-related HCC.

Andreas Kroh, Jeanette Walter, Athanassios Fragoulis, Diana Möckel, Twan Lammers, Fabian Kiessling, Julia Andruszkow, Christian Preisinger, Maren Egbert, Long Jiao and 7 more

Open access · goldAbstract read
In one paragraph

Article in Neoplasia (New York, N.Y.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 3 countries.

Andreas KrohDepartment of General, Visceral and Transplantation Surgery, RWTH Aachen University Hospital, Aachen, Germany. Electronic address: akroh@ukaachen.de.
Jeanette WalterDepartment of General, Visceral and Transplantation Surgery, RWTH Aachen University Hospital, Aachen, Germany; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, RWTH Aachen University Hospital, Aachen, Germany.
Athanassios FragoulisDepartment of Anatomy and Cell Biology, RWTH Aachen University Hospital Aachen, Germany.
Diana MöckelInstitute for Experimental Molecular Imaging (ExMI), RWTH Aachen University Hospital, Aachen, Germany.
Twan LammersInstitute for Experimental Molecular Imaging (ExMI), RWTH Aachen University Hospital, Aachen, Germany.
Fabian KiesslingInstitute for Experimental Molecular Imaging (ExMI), RWTH Aachen University Hospital, Aachen, Germany.
Julia AndruszkowInstitute of Pathology, RWTH Aachen University Hospital, Aachen, Germany.
Christian PreisingerProteomics Facility, Interdisciplinary Center for Clinical Research (IZKF) Aachen, Medical School, RWTH Aachen University Hospital, Aachen, Germany.
Maren EgbertDepartment of General, Visceral and Transplantation Surgery, RWTH Aachen University Hospital, Aachen, Germany.
Long JiaoDepartment of General, Visceral and Transplantation Surgery, RWTH Aachen University Hospital, Aachen, Germany; Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, PR China.
Roman M EickhoffDepartment of General, Visceral and Transplantation Surgery, RWTH Aachen University Hospital, Aachen, Germany.
Daniel HeiseDepartment of General, Visceral and Transplantation Surgery, RWTH Aachen University Hospital, Aachen, Germany.
Nikolaus BerndtDepartment of Molecular Toxicology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, Germany; Institute of Computer-assisted Cardiovascular Medicine, Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Thorsten CramerDepartment of General, Visceral and Transplantation Surgery, RWTH Aachen University Hospital, Aachen, Germany.
Ulf Peter NeumannDepartment of General, Visceral and Transplantation Surgery, RWTH Aachen University Hospital, Aachen, Germany; Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands.
Antje EgnersDepartment of General, Visceral and Transplantation Surgery, RWTH Aachen University Hospital, Aachen, Germany.
Tom Florian UlmerDepartment of General, Visceral and Transplantation Surgery, RWTH Aachen University Hospital, Aachen, Germany; Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands.
Universitätsklinikum Aachen · DEMaastricht University Medical Centre · NLHumboldt-Universität zu Berlin · DENanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity and associated nonalcoholic steatohepatitis (NASH) are on the rise globally. NASH became an important driver of hepatocellular carcinoma (HCC) in recent years. Activation of the central metabolic regulator mTOR (mechanistic target of rapamycin) is frequently observed in HCCs. However, mTOR inhibition failed to improve the outcome of HCC therapies, demonstrating the need for a better understanding of the molecular and functional consequences of mTOR blockade. We established a murine NASH-driven HCC model based on long-term western diet feeding combined with hepatocellular mTOR-inactivation. We evaluated tumor load and whole-body fat percentage via µCT-scans, analyzed metabolic blood parameters and tissue proteome profiles. Additionally, we used a bioinformatic model to access liver and HCC mitochondrial metabolic functions. The tumor burden was massively increased via mTOR-knockout. Several signs argue for extensive metabolic reprogramming of glucose, fatty acid, bile acid and cholesterol metabolism. Kinetic modeling revealed reduced oxygen consumption in KO-tumors. NASH-derived HCC pathogenesis is driven by metabolic disturbances and should be considered separately from those caused by other etiologies. We conclude that mTOR functions as tumor suppressor in hepatocytes especially under long-term western diet feeding. However, some of the detrimental consequences of this diet are attenuated by mTOR blockade.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsNon-alcoholic Fatty Liver DiseaseAnimalsHumansMiceTOR Serine-Threonine KinasesTumor BurdenmTOR protein, mouseTOR Serine-Threonine KinasesHepatocellular carcinomaLiver metabolismMetabolic reprogrammingmTORNonalcoholic steatohepatitis

Identifiers

PMID37976569
PMCPMC10685311
OpenAlexW4388682899

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.